有机化学 ›› 2016, Vol. 36 ›› Issue (5): 1080-1087.DOI: 10.6023/cjoc201510034 上一篇    下一篇

研究论文

熊果酸A环衍生物的合成及抗肿瘤活性研究

孟艳秋, 曹佳, 汤义, 鹿学宇, 刘立伟   

  1. 沈阳化工大学制药工程教研室 沈阳 110142
  • 收稿日期:2015-10-28 修回日期:2015-12-16 发布日期:2016-01-04
  • 通讯作者: 孟艳秋 E-mail:mengyanqiu@hotmail.com
  • 基金资助:

    国家自然科学基金(No.21372156)、辽宁省教育厅高等学校优秀人才支持计划(No.LR2013017)和沈阳市科学技术计划(No.F16-230-6-00)资助项目.

Synthesis and Anti-tumor Activity of Derivatives of Ring A of Ursolic Acid

Meng Yanqiu, Cao Jia, Tang Yi, Lu Xueyu, Liu Liwei   

  1. Department of Pharmaceutical Engineering, Shenyang University of Chemical Technology, Shenyang 110142
  • Received:2015-10-28 Revised:2015-12-16 Published:2016-01-04
  • Supported by:

    Project supported by the National Natural Science Foundation of China (No. 21372156), the Education Department of Higher School Outstanding Talent Support Program in Liaoning Province (No. LR2013017) and the Science and Technology Project in Shenyang (No. F 16-230-6-00) .

以天然产物熊果酸为起始原料,在A环上引入含氮、氧杂环,同时对其C(28)位羧基进行酰胺化结构修饰,设计合成了10个新的熊果酸衍生物,其结构经过1H NMR、13C NMR、MS和元素分析确认.采用3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐(MTT)法,选用高表达人口腔表皮样癌细胞(KB)和人胃癌细胞(SGC7901)对它们进行初步的体外抗肿瘤活性研究.结果表明,所测化合物对KB和SGC7901肿瘤细胞的抑制活性均明显强于熊果酸,其中化合物UA4-1UA4-2对SGC7901肿瘤细胞的抑制效果显著,在10μg/mL浓度下IC50值分别为0.289和0.04μmol/L,活性明显高于已上市药物吉非替尼(IC50=1.03μmol/L).

关键词: 五环三萜类化合物, 熊果酸, 抗肿瘤活性

Ten derivatives were successfully synthesized by the introduction of nitrogen-and oxygen-containing heterocyclic compounds at ring A and the modification of the amidation at C(28) position in the natural product ursolic acid, which structures were characterized by 1H NMR, 13C NMR, MS and elemental analysis. Their anti-tumor activities against KB and SGC7901 cells in vitro were evaluated by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. These results indicated that all of derivatives can inhibit cell proliferation of KB and SGC7901 cells better than ursolic acid (UA), and UA4-1 (IC50=0. 289 μmol/L) and UA4-2 (IC50=0. 04 μmol/L) were also found to have especially more potent inhibitory activity on SGC7901 tumor cells than that of the positive control drug gefitinib (IC50=1. 03 μmol/L).

Key words: pentacyclic trierpenoid, ursolic acid, anti-tumor activity